International Myeloma Foundation

International Myeloma Foundation Founded in 1990, the International Myeloma Foundation is the first and largest myeloma organization. Improving Lives, Finding the Cure. and worldwide.
(1)

Research
The International Myeloma Foundation is dedicated to finding a cure for those living with multiple myeloma. We have a range of initiatives to make this happen. Education
Because "Knowledge Is Power," the IMF brings educational seminars and workshops to communities near you, and provides a library of publications on multiple myeloma care. Support
Since our inception in 1990, the IMF has su

pported and met in-person with more than 3,000 myeloma patients globally. Advocacy
The IMF’s Advocacy team has educated and empowered thousands of individuals who make a positive impact each year on issues critical to the myeloma community in the U.S.

Are you newly diagnosed with multiple myeloma and considered frail or intermediate fit—not getting a stem cell transplan...
06/14/2025

Are you newly diagnosed with multiple myeloma and considered frail or intermediate fit—not getting a stem cell transplant? This clinical trial studying 3-drug induction + 1 or 2-drug maintenance may be a fit for you. Learn more & see if you’re eligible: https://mmsm.link/4jPceHJ

Myeloma community, will we see you at the IMF Regional Community Workshop (RCW) in Waltham, MA on September 27? Connect...
06/13/2025

Myeloma community, will we see you at the IMF Regional Community Workshop (RCW) in Waltham, MA on September 27? Connect with the myeloma community, build your support network, ask the experts your questions, find support in your community, and more. Save your spot: https://mmsm.link/3RdElVc

06/13/2025

Can new immunotherapies be used for myeloma without using chemotherapy first? IMF Chief Medical Officer Dr. Joseph Mikhael answers in this short clip. Watch the full patient Q&A video with Dr. Mikhael at https://www.myeloma.org/node/11744

06/13/2025

At the IMF, we want to help you through this complicated journey. We are here for you! Contact our InfoLine at www.myeloma.org/infoline and watch the full video on bispecific antibodies with IMF CMO Dr. Joe Mikhael at www.myeloma.org/node/11751

This Pride Month, we honor the strength and resilience of our LGBTQ+ patients, care partners, and myeloma community memb...
06/12/2025

This Pride Month, we honor the strength and resilience of our LGBTQ+ patients, care partners, and myeloma community members. Your stories matter. Your health matters. You belong. ❤️

We hope to see you at our M-Power community workshop on 6/21—learn about heritage, health empowerment, and hope from a...
06/12/2025

We hope to see you at our M-Power community workshop on 6/21—learn about heritage, health empowerment, and hope from a panel of global myeloma experts. The workshop is FREE, but spots are LIMITED—register now to save your spot! https://mmsm.link/45uIzzX

Bispecific antibodies are changing how we treat relapsed myeloma—but they can raise your risk of infection. In this epis...
06/12/2025

Bispecific antibodies are changing how we treat relapsed myeloma—but they can raise your risk of infection. In this episode of Myeloma Made Simple, Dr. Joseph Mikhael breaks down how to reduce that risk with four simple steps. This episode of Myeloma Made Simple is supported by Pfizer. https://www.myeloma.org/node/11751

06/11/2025

What’s next in myeloma?
At Summit, top experts are unpacking:
MGUS to myeloma progression
Risk stratification updates
Immunotherapy sequencing
And more

06/11/2025

Yesterday at the IMWG Summit in Milan, we honored Dr. Sagar Lonial and Dr. Sonja Zweegman for their groundbreaking work in myeloma care with the Kyle and Durie Achievement Awards.
Read more: https://mmsm.link/3FTdVWy

06/11/2025

"Why did my light chains spike after talquetamab—should I worry?" IMF Chief Medical Officer Dr. Joseph Mikhael answers this patient question in this short clip. Watch the full video with Dr. Mikhael: https://www.myeloma.org/node/11744

Why We've Redefined "High-Risk" Multiple Myeloma—And What It Means for YouNot all multiple myeloma patients respond to t...
06/10/2025

Why We've Redefined "High-Risk" Multiple Myeloma—And What It Means for You

Not all multiple myeloma patients respond to treatment in the same way. Some do very well with today’s powerful new therapies, while others, despite getting the same care, face a much tougher road. These are patients we often describe as having “high-risk multiple myeloma (HRMM).”

But there’s one big problem: the way we’ve traditionally defined “high-risk” is based on outdated information. As science and treatments have evolved, our definitions haven’t kept up—until now.

To close this gap, the International Myeloma Foundation's International Myeloma Working Group (IMWG) and the International Myeloma Society (IMS) brought together leading experts from around the world to update what it means to have “high-risk” myeloma. The result is a new, more accurate way to identify high-risk patients using modern genetic, molecular, and clinical data.

So why is this important? Because a better definition means better care.

1. For doctors, it helps them spot high-risk patients earlier and tailor treatment more precisely. Instead of using a “one-size-fits-all” approach, this new system supports risk-adapted care, meaning treatments can be adjusted based on how aggressive the disease is.

2. For researchers, this new definition allows clinical trials to more clearly identify which patients are truly high-risk, leading to more meaningful results and the development of therapies tailored to those who need them most. It also enables more accurate comparisons of treatment outcomes, since high-risk patients are often a subgroup within broader, all-comer trials.

3. For patients, it means getting more realistic, personalized information about your prognosis—and potentially receiving more intensive treatment earlier, when it can make the biggest difference.

So, What’s changed?
The new Consensus Genomic Staging (CGS) system analyzes key genetic features within myeloma cells, including specific gene deletions, mutations, and chromosomal changes. By incorporating these details, we will provide a more precise identification of high-risk disease. This system is the most comprehensive and data-driven approach developed to date.

What will be the impact?
Faster, more accurate diagnosis of high-risk disease
More targeted treatment plans
Smarter, more effective clinical trials
Stronger global collaboration to improve outcomes

This is a big step forward in ensuring that every patient gets the right care, at the right time, with the right information. And it’s all part of the myeloma community’s mission to leave no one behind. Get access to the publication at ASCO pubs, here: https://ascopubs.org/doi/10.1200/JCO-24-01893

If you or someone you love is living with myeloma, please reach out to the International Myeloma Foundation. We’re here for you. The IMF’s InfoLine is available to answer your myeloma-related questions and concerns. Call us at 1-818-487-7455, email us at [email protected], or schedule your call at a time that works best for you at: https://www.myeloma.org/infoline.

Address

4400 Coldwater Canyon Avenue , Suite 300
Los Angeles, CA
91604

Opening Hours

Monday 8:30am - 4:15pm
Tuesday 9am - 4:15pm
Wednesday 8:30am - 4:15pm
Thursday 8:30am - 4:15pm
Friday 8:30am - 4:15pm

Website

Alerts

Be the first to know and let us send you an email when International Myeloma Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category

About the IMF

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest foundation focusing specifically on multiple myeloma. The Foundation’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure by focusing on four key areas: research, education, support, and advocacy.